

a.) Amendments to the Claims

1. (Cancelled)

2. (Cancelled)

3. (Previously Presented) A method of inhibiting the leakage of an encapsulated drug in the presence of a biological component, which comprises the steps of:

selecting a lipid from the group consisting of phospholipid, glyceroglycolipid and sphingoglycolipid with a phase transition temperature higher than *in vivo* temperature; and

encapsulating said drug within liposomes consisting of said lipid, wherein said liposomes have an average particle size of 120 to 500 nm.

4. (Previously Presented) The method of inhibiting the leakage according to claim 3, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine, and polyethylene glycol-modified phospholipid.

5. (Previously Presented) The method of inhibiting the leakage according to claim 3, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine, and polyethylene glycol-modified

phospholipid.

6. (Cancelled)

7. (Cancelled)

8. (Previously Presented) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein the biological component is a blood component.

9. (Previously Presented) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein the drug encapsulated is an indolocarbazole derivative.

10. (Previously Presented) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein the drug encapsulated is an antitumor agent.

11. (Previously Presented) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein the drug encapsulated is an antibiotic.

12. (Previously Presented) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein the drug encapsulated is a pharmaceutically

active substance.

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Previously Presented) A pharmaceutical composition comprising a drug encapsulated in a liposome with an average particle size of 120 to 500 nm, and consisting of lipid having a phase transition temperature higher than *in vivo* temperature selected from the group consisting of phospholipid, glyceroglycolipid and sphingoglycolipid.

17. (Cancelled)

18. (Cancelled)

19. (Previously Presented) The liposome preparation according to claim 16, wherein the lipid comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid.

20. (Previously Presented) The liposome preparation according to claims 16, wherein the lipid comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine and polyethylene glycol-modified phospholipid.

21. (Cancelled)

22. (Previously Presented) The liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is an indolocarbazole derivative.

23. (Previously Presented) The liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is an antitumor agent.

24. (Previously Presented) The liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is an antibiotic.

25. (Previously Presented) The liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is a pharmaceutically active substance.

26. (Previously Presented) The method of inhibiting the leakage

according to claim 8, wherein the drug encapsulated is an indolocarbazole derivative.

27. (Previously Presented) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is an antitumor agent.

28. (Previously Presented) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is an antibiotic.

29. (Previously Presented) The method of inhibiting the leakage according to claim 8, wherein the drug encapsulated is a pharmaceutically active substance.

30. (Previously Presented) The method of inhibiting the leakage according to any one of claims 3 to 5, wherein said liposome comprises at least two bilayers of said lipid.

31. (Previously Presented) The method of inhibiting the leakage according to claim 26, wherein said liposome comprises at least two bilayers of said lipid.

32. (Previously Presented) The method of inhibiting the leakage according to claim 27, wherein said liposome comprises at least two bilayers of said lipid.

33. (Previously Presented) The method of inhibiting the leakage according

to claim 28, wherein said liposome comprises at least two bilayers of said lipid.

34. (Previously Presented) The method of inhibiting the leakage according to claim 29, wherein said liposome comprises at least two bilayers of said lipid.

35. (Previously Presented) The liposome preparation according to any one of claims 16, 19 or 20 wherein said liposome comprise at least two bilayers of said lipid.

36. (Previously Presented) The liposome preparation according to claim 22, wherein said liposome comprise at least two bilayers of said lipid.

37. (Previously Presented) The liposome preparation according to claim 23, wherein said liposome comprise at least two bilayers of said lipid.

38. (Previously Presented) The liposome preparation according to claim 24, wherein said liposome comprise at least two bilayers of said lipid.

39. (Previously Presented) The liposome preparation according to claim 25, wherein said liposome comprise at least two bilayers of said lipid.

40. (New) A method of inhibiting the leakage of an encapsulated drug in the presence of a biological component, which comprises the steps of:

selecting a lipid with a phase transition temperature higher than *in vivo* temperature; and

encapsulating said drug within liposomes comprising said lipid, wherein said liposomes do not comprise cholesterol and said liposomes have an average particle size of 120 to 500 nm.

41. (New) A pharmaceutical composition comprising a drug encapsulated in a liposome with an average particle size of 120 to 500nm, said liposome comprising a lipid having a phase transition temperature higher than *in vivo* temperature, wherein said liposome does not comprise cholesterol.